Publications

Molecular characterization of genes encoding CTX-M-134, TEM-207 and TEM-212 detected among Escherichia coli clinical isolates from USA hospitals, Lead author: Castanheira M, presented at 25th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 25-29, 2015, Copenhagen, Denmark

Oritavancin in vitro activity against the most prevalent antibiogram resistance patterns among MRSA, including MDR strains from patients in European hospitals (2010-2013), Lead author: Mendes RE, presented at 25th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 25-29, 2015, Copenhagen, Denmark

Antimicrobial Activity of Ceftolozane/Tazobactam and Comparator Agents Tested against Pseudomonas aeruginosa Isolates from 15 European Countries and Israel (2013), Lead author: Sader HS, presented at 25th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 25-29, 2015, Copenhagen, Denmark

Antimicrobial Activity of Ceftolozane/Tazobactam and Comparator Agents Tested against Enterobacteriaceae Isolates from 15 European Countries and Israel (2013), Lead author: Farrell DJ, presented at 25th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 25-29, 2015, Copenhagen, Denmark

Update of the telavancin in vitro activity against SA and CoNS, including isolates with decreasing susceptibility for comparator agents in European hospitals (2013), Lead author: Mendes RE, presented at 25th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 25-29, 2015, Copenhagen, Denmark

Potent in vitro activity of telavancin against EU strep. isolates displaying an array of antibiogram profiles, Lead author: Mendes RE, presented at 25th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 25-29, 2015, Copenhagen, Denmark

In vitro activity of oritavancin against streptococci, including macrolide- and/or lincosamide (constitutive)-resistant and MDR isolates from EU hospitals (2010-2013), Lead author: Mendes RE, presented at 25th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 25-29, 2015, Copenhagen, Denmark

Sustained potent activity of dalbavancin when tested against MDR staphylococcal and streptococcal isolates responsible for documented infection in EU (2011-2013), Lead author: Mendes RE, presented at 25th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 25-29, 2015, Copenhagen, Denmark

Maximizing antibacterial activity of polymyxin B: Microbiological component analyses alone and in combination, Lead author: Kassamali Z, presented at 25th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 25-29, 2015, Copenhagen, Denmark

Update on dalbavancin activity tested against Gram-positive isolates causing documented skin and soft tissue infections in USA and European hospitals (2011-2013), Lead author: Medes RE, presented at 25th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 25-29, 2015, Copenhagen, Denmark

Debio 1452 MIC QC Range with S. aureus ATCC 29213 Using a Multi-laboratory Study Design, Lead author: Flamm RK, presented at 25th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 25-29, 2015, Copenhagen, Denmark

Minocycline activity tested against A. baumannii, B. cepacia, S. maltophila, and select Enterobacteriaceae isolates from a European surveillance program (2013), Lead author: Flamm RK, presented at 25th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 25-29, 2015, Copenhagen, Denmark

Tigecycline activity tested against >11,000 isolates of Acinetobacter spp. collected worldwide in 2004-2013, Lead author: Sader HS, presented at 25th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 25-29, 2015, Copenhagen, Denmark

In vitro activity of dalbavancin tested against S. pneumoniae responsible for documented infection in medical centres in five continents worldwide (2011-2013), Lead author: Mendes RE, presented at 25th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 25-29, 2015, Copenhagen, Denmark

Antimicrobial potency of lefamulin (BC-3781) tested against S. pneumoniae with defined serotypes, including MDR isolates causing lower RTI in the USA, Lead author: Mendes RE, presented at 25th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 25-29, 2015, Copenhagen, Denmark

Accuracy of Predicting Oritavancin Susceptibility using Vancomycin Surrogate Susceptibility Testing of GP from EU, Lead author: Jones RN, presented at 25th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 25-29, 2015, Copenhagen, Denmark

In vitro activity of AZD0914, a novel bacterial DNA gyrase/topoisomerase IV inhibitor, against clinically relevant Gram-positive and fastidious Gram-negative pathogens. by Biedenbach DJ, Huband MD, Hackel M, de Jonge BL, Sahm DF and Bradford PA published in Antimicrob. Agents. Chemother. 2015; 59 (10): 6053-6063

Detection of a new cfr-like gene, cfr(B), in Enterococcus faecium recovered from human specimens in the United States: Report from The SENTRY Antimicrobial Surveillance Program. by Deshpande LM, Ashcraft DS, Kahn HP, Pankey G, Jones RN, Farrell DJ and Mendes RE published in Antimicrob. Agents. Chemother. 2015; 59 (10): 6256-6261,

Telavancin activity when tested by a revised susceptibility testing method against uncommonly isolated Gram-positive pathogens responsible for documented infections in hospitals worldwide (2011-2013). by Mendes RE, Sader HS, Flamm RK, Farrell DJ and Jones RN published in J. Global Antimicrob. Res. 2015; 3 (1): 36-39

Ceftazidime/avibactam tested against Gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumonia. by Sader HS, Castanheira M, Flamm RK, Mendes RE, Farrell DJ and Jones RN. published in Int. J. Antimicrob. Agents. 2015; 46 (1): 53-59

Activity of ceftaroline and comparator agents tested against Staphylococcus aureus from patients with bloodstream infections in US medical centres (2009–13). by Sader HS, Farrell DJ, Flamm RK and Jones RN. published in J. Antmicrob. Chemother. 2015; 70 (7): 2053-2056,

Analysis of 5-year trends in daptomycin activity tested against Staphylococcus aureus and enterococci from European and US hospitals (2009-2013). by Sader HS, Farrell DJ, Flamm RK and Jones RN published in J. Global. Antimicrob. Res. 2015; 3: 161-165

Determination of disk diffusion and MIC quality control guidelines for solithromycin, a novel fluoroketolide antibacterial against Neisseria gonorrhoeae. by Riedel S, Ross JE, Farrell DJ, Flamm RK and Jones RN published in J. Clin. Microbiol.: 2015; 53 (12): 3888-3890

Initial broth microdilution quality control guidelines for Debio 1452, a FabI inhibitor antimicrobial agent. by Ross JE, Flamm RK and Jones RN published in Antimicrob. Agents Chemother. 2015; 59 (11): 7151-7152

Analysis of vancomycin susceptibility testing results for presumptive categorization of telavancin. by Mendes RE, Farrell DJ, Flamm RK, Sader HS and Jones RN published in J. Clin. Microbiol. 2015; 53 (8): 2727-2730

Genotypic characterization of methicillin-mesistant Staphylococcus aureus recovered at baseline from Phase 3 pneumonia clinical trials for ceftobiprole. by Mendes RE, Deshpande LM, Costello AJ, Farrell DJ, Jones RN and Flamm RK published in Microb. Drug Resist.: 2016; 22 (1): 53-58,

Microbiological assessment of polymyxin B components tested alone and in combination. by Kassamali Z, Prince RA, Danziger LH, Rotschafer JC, Rhomberg PR and Jones RN published in Antimicrob. Agents. Chemother. 2015; 59 (12): 7823-7825

Telavancin activity tested against Gram-positive clinical isolates from European, Russian and Israeli hospitals (2011-2013) using a revised broth microdilution testing method: Redefining the baseline activity of telavancin. by Mendes RE, Flamm RK, Farrell DJ, Sader HS and Jones RN published in J. Chemother. 2016; 28 (2): 83-88

Ceftazidime-avibactam activity when tested against ceftazidime-nonsusceptible Citrobacter spp., Enterobacter spp., Serratia marcescens, and Pseudomonas aeruginosa from Unites States medical centers (2011-2014). by Sader HS, Castanheira M, Farrell DJ, Flamm RK and Jones RN published in Diagn. Microbiol. Infect. Dis. 2015; 83 (4): 389-394

Arbekacin activity against contemporary clinical bacteria isolated from patients hospitalized with pneumonia. by Sader HS, Rhomberg PR, Farrell DJ and Jones RN published in Antimicrob. Agents. Chemother. 2015; 59 (6): 3263-3270

Differences in potency and categorical agreement between colistin and polymyxin B when testing 15,377 clinical strains collected worldwide. by Sader HS, Rhomberg PR, Farrell DJ and Jones RN. published in Diagn. Microbiol. Infect. Dis. 2015; 83 (4): 379-381.

Noninvasive Streptococcus pneumoniae serotypes recovered from hospitalized adult patients in the United States in 2009 to 2012. by Mendes RE, Hollingsworth RC, Costello A, Jones RN, Isturiz RE, Hewlett D, Jr. and Farrell DJ published in Antimicrob. Agents. Chemother. 2015; 59 (9): 5595-5601

Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases. by Basarab GS, Kern GH, McNulty J, Mueller JP, Lawrence K, Vishwanathan K, Alm RA, Barvian K, Doig P, Galullo V, Gardner H, Gowravaram M, Huband M, Kimzey A, Morningstar M, Kutschke A, Lahiri SD, Perros M, Singh R, Schuck VJ, Tommasi R, Walkup G and Newman JV published in Sci. Rep. 2015; 5: 11827

In vitro activity of RX-P873 against Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter baumannii. by Flamm RK, Rhomberg PR, Jones RN and Farrell DJ published in Antimicrob. Agents Chemother. 2015; 59 (4): 2280-2285

Validation of Sensititre dry-form broth microdilution panels for susceptibility testing of ceftazidime-avibactam, a broad-spectrum-beta-lactamase inhibitor combination. by Jones RN, Holliday NM and Krause KM published in Antimicrob. Agents Chemother. 2015; 59 (8): 5036-5039,

In vitro activity of linezolid as assessed through the 2013 LEADER surveillance program. by Flamm RK, Mendes RE, Hogan PA, Ross JE, Farrell DJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 2015; 81 (4): 283-289

MSSA ST398/t034 carrying a plasmid-mediated cfr and erm(B) in Brazil. by Gales AC, Deshpande LM, de Souza AG, Pignatari AC and Mendes RE published in J. Antimicrob. Chemother. 2015; 70 (1): 303-305

Baseline activity of telavancin when tested against Gram-positive clinical isolates responsible for documented infections in USA hospitals (2011-2012) applying the revised susceptibility testing method. by Mendes RE, Farrell DJ, Sader HS, Flamm RK and Jones RN published in Antimicrob. Agents Chemother. 2015; 59 (1): 702-706

Antimicrobial activity of solithromycin against serotyped macrolide-resistant Streptococcus pneumoniae isolates collected from U.S. medical centers in 2012. by Farrell DJ, Mendes RE and Jones RN published in Antimicrob. Agents Chemother. 2015; 59 (4): 2432-2434

Isavuconazole, micafungin, and 8 comparator antifungal agents’ susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: Temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and proposed epidemiological cutoff values. by Pfaller MA, Rhomberg PR, Messer SA, Jones RN and Castanheira M published in Diagn. Microbiol. Infect. Dis. 2015; 82 (4): 303-313

In vitro antibacterial activity of AZD0914 against human mycoplasmas and ureaplasmas. by Waites KB, Crabb DM, Duffy LB and Huband MD published in Antimicrob. Agents. Chemother. 2015; 59 (6): 3627-3629

Ceftazidime-avibactam activity tested against multidrug-resistant Pseudomonas aeruginosa isolated from United States Medical Centers (2012-2013). by Sader HS, Castanheira M, Mendes RE, Flamm RK, Farrell DJ and Jones RN. published in Antimicrob. Agents Chemother.. 2015; 59 (6): 3656-3659

Antimicrobial activity of ceftaroline tested against bacterial isolates causing respiratory tract and skin and skin structure infections in US medical centers in 2013. by Sader HS, Farrell DJ, Mendes RE, Flamm RK, Castanheira M and Jones RN published in Diagn. Microbiol. Infect. Dis. 2015; 82 (1): 78-84

Cytotoxic virulence predicts mortality in nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus. by Rose HR, Holzman RS, Altman DR, Smyth DS, Wasserman GA, Kafer JM, Wible M, Mendes RE, Torres VJ and Shopsin B published in J. Infect. Dis. 2015; 211 (12): 1862-1874

Ceftazidime-avibactam activity tested against Enterobacteriaceae from United States hospitals (2011-2013) and characterization of beta-lactamase producing strains. by Castanheira M, Mills JC, Costello SE, Jones RN and Sader HS published in Antimicrob. Agents Chemother. 2015; 59 (6): 3509-3517

Activity of Debio1452, a FabI inhibitor with potent activity against S. aureus and coagulase-negative Staphylococcus spp., including multidrug-resistant strains. by Flamm RK, Rhomberg P, Kaplan N, Jones RN and Farrell DJ published in Antimicrob. Agents Chemother. 2015; 59 (5): 2583-2587

In vitro activity of dalbavancin against drug resistant Staphylococcus aureus from a global surveillance program. by McCurdy SP, Jones RN, Mendes RE, Puttagunta S and Dunne MW published in Antimicrob. Agents Chemother. 2015; 59 (8): 5007-5009

Accuracy of the ThermoFisher Scientific (Sensititre^TM) dry-form broth microdilution MIC product when testing ceftaroline. by Jones RN, Holliday NM and Critchley IA. published in Diagn. Microbiol. Infect. Dis. 2015; 81 (4): 280-282

Ceftaroline activity against bacterial pathogens frequently isolated in U.S. medical centers: results from five years of the AWARE surveillance program. by Sader HS, Flamm RK, Streit J, Farrell DJ and Jones RN published in Antimicrob. Agents Chemother. 2015; 59 (4): 2458-2461,

Activity of ceftaroline and comparator agents tested against Staphylococcus aureus from patients with bloodstream infections in US medical centres (2009–13). by Sader HS, Farrell DJ, Flamm RK and Jones RN published in J. Antmicrob. Chemother. 2015; 70 (7): 2053-2056, 2015